
Feb 19 (Reuters) - Valneva SE VLS.PA:
VALNEVA REPORTS PRELIMINARY UNAUDITED 2025 REVENUE AND CASH AND PROVIDES 2026 OUTLOOK
FY TOTAL REVENUES OF EUR 174.7 MILLION
FIRST PHASE 3 DATA READOUT FOR LYME DISEASE VACCINE CANDIDATE ANTICIPATED IN FIRST HALF OF 2026
TOTAL REVENUES FOR 2026 ARE EXPECTED IN RANGE OF EUR 155-170 MILLION